March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma (FL)..
If you're reading this, you or maybe one of your loved ones is on a journey that no one ever plans to take—the path of facing cancer. We understand that this road is filled with uncertainties, fears, and moments when it feel..
ស្វែងយល់ពីវិទ្យាសាស្ត្រនៅពីក្រោយការព្យាបាល CAR T Cell នៅប្រទេសឥណ្ឌា! ស្វែងយល់ពីរបៀបដែលការព្យាបាលបដិវត្តនេះបំប្លែងកោសិកាភាពស៊ាំរបស់អ្នកទៅជាអ្នកប្រយុទ្ធនឹងជំងឺមហារីក។ សូមអានប្លក់របស់យើងឥឡូវនេះ ដើម្បីស្វែងយល់បន្ថែមអំពីការព្យាបាលអព្ភូតហេតុនេះ និងរបៀប ..
Have you ever wondered if there is a powerful way to fight cancer? Now just imagine if one day you found a ray of hope in your fight against cancer, a treatment that uses the power of your body's own immune system to target an..
ខែឧសភា ឆ្នាំ 2023៖ សម្រាប់អ្នកជំងឺពេញវ័យដែលមានជំងឺមហារីកកូនកណ្តុរប្រភេទ B-cell lymphoma (HGBL) ដែលមិនបានបញ្ជាក់ផ្សេង (NOS) ឬរីករាលដាលនៃជំងឺមហារីកកូនកណ្តុរ B-cell lymphoma (DLBCL) ដែលមិនទាន់បានទទួលការព្យាបាលពីមុន និងមានសន្ទស្សន៍ព្យាករណ៍អន្តរជាតិ។
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to stati..
Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma. In BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobr..
Feb 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) is approved by FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA was used to assess effectiveness in CLL/SLL patients who had not recei..
ខែវិច្ឆិកា ឆ្នាំ 2022៖ ការរួមបញ្ចូលគ្នានៃ doxorubicin, vincristine, etoposide, prednisone, និង cyclophosphamide ជាមួយ brentuximab vedotin (Adcetris, Seagen, Inc.) ត្រូវបានអនុម័តដោយរដ្ឋបាលចំណីអាហារ និងឪសថសម្រាប់ប្រើប្រាស់លើកុមារ។